Advertisement


Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

2024 ASCO Annual Meeting

Advertisement

Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and more broadly disseminate this evidence-based care model (LBA3).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We've seen tremendous breakthroughs in novel therapeutics for lung cancer, which is incredibly exciting. At the same time, most patients with advanced lung cancer will, at some point along their disease trajectory, experience disabling physical and psychological symptoms, poor quality of life, financial stressors, and often, functional changes and worries about what the future might hold. Their caregivers, their loved ones, their friends and family share in this distress. To address these unmet needs, ASCO and other professional societies have recommended the early integration of palliative and oncology care from the time of diagnosis of advanced cancer. These guidelines are based on evidence from multiple clinical trials demonstrating the efficacy of early palliative care for improving quality of life, mood symptoms, coping, and other key outcomes in this vulnerable population. However, and unfortunately, most patients and their families do not receive this evidence-based care due to multiple barriers, chief among them being the limited availability of specialty trained palliative care clinicians. As our team was conceiving of a way to overcome these barriers, one potential solution that seemed highly feasible and potentially acceptable was the use of telehealth to deliver video visits for early palliative care. Therefore, we constructed a large-scale comparative effectiveness trial to test the delivery of early palliative care, either via video visits or in-person visits, for patients with advanced lung cancer and their families. The primary aim was to assess the equivalence of these two modalities on patient-reported quality of life at 24 weeks. We enrolled 1,250 patients and 548 caregivers, and randomly assigned them in a one-to-one fashion, either to early integrated palliative care delivered via video or early integrated palliative care delivered in person, in clinic. Those patients followed the same protocol in both study groups by meeting with the palliative care clinician at least every four weeks over the course of their illness. In addition, a patient and their caregiver would complete self-report measures of quality of life, satisfaction with care, their mood symptoms, and other self-report measures prior to randomization, and then again every 12 weeks up through 48 weeks. In our analysis of these data, we found that the two study groups demonstrated equivalent effects on patient-reported quality of life at 24 weeks. In addition, patients and caregivers also similarly reported no difference in their satisfaction with care whether the delivery of the care was via video or in person. And lastly, patients and caregivers did not report any differences in their mood symptoms. We are very pleased with these findings showing the equivalence between these two modalities for improving patient's quality of life as well as their caregiver outcomes. These findings have implications for improving access to early integrated palliative care, particularly for patients who live in far distances from their clinics, as well as for those who may be frail or have comorbid conditions that make getting to the clinic very challenging. Our hope is that these findings will inform policy decisions and advocates in trying to ensure the coverage of telehealth services for patients with advanced cancer so that they can continue to receive evidence-based early palliative care.

Related Videos

Breast Cancer

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them to enhance survival and quality of life.

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Kidney Cancer

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study

Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Lung Cancer

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).

Advertisement

Advertisement




Advertisement